A Phase 1b Multicenter, Randomized, Single-Masked, Sham-Controlled Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients with Progressing Open Angle Glaucoma
Latest Information Update: 01 Nov 2024
Price :
$35 *
At a glance
- Drugs ONL 1204 (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions
- Sponsors ONL Therapeutics
- 29 Oct 2024 Status changed from active, no longer recruiting to completed.
- 13 Jul 2023 Planned End Date changed from 1 Sep 2023 to 1 Oct 2024.
- 13 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Apr 2024.